MS disease-modifying therapies in FAERS: 820,731 adverse-event reports by the numbers

The FDA Adverse Event Reporting System (FAERS) holds 820,731 individual safety reports that name at least one multiple sclerosis disease-modifying therapy (DMT) — a beta interferon, glatiramer acetate, natalizumab, an oral agent such as dimethyl fumarate, fingolimod, or teriflunomide, or an anti-CD20 antibody such as ocrelizumab or ofatumumab — in any role, from the first structured records through the openFDA extract dated June 8, 2026. Cumulatively the class is led by the legacy injectables and the alpha-4-integrin agent: interferon beta appears in 222,546 reports, natalizumab (Tysabri) in 179,335, and dimethyl fumarate (Tecfidera) in 122,095, reflecting decades of use; the newer anti-CD20 antibodies ocrelizumab (Ocrevus, 59,623) and ofatumumab (Kesimpta, 31,955) lead only the most recent reporting years. Of the class total, 367,990 reports — 44.8 percent — carry an FDA seriousness flag, and 27,216 (3.3 percent) record a death flag or a fatal outcome, a far lower mortality share than oncology or anticoagulant classes. The most distinctive feature of this class is not a reaction at all — it is the reporter mix: consumers filed 527,294 of the reports (64.2 percent), while lawyers filed just 137 (under 0.02 percent).

This article is a class-level descriptive read of MS DMT reporting in FAERS, written for specialty-pharmacy, pharmacovigilance, medical-affairs, and neurology market-access teams who meet these numbers in step-therapy design, PML risk management, benefit routing, and patient-hub operations. Every figure here is computed from the public openFDA FAERS extract (20,328,575 total reports, export dated 2026-06-08). It is not a disproportionality signal analysis, it is not a safety claim, and it is not incidence data. FAERS is a spontaneous-reporting system: it captures what was reported, never what was caused, and it has no exposure denominator. For the class-wide FAERS methodology and the database aggregate picture, see the companion analysis of 20 million FAERS reports and the FAERS report-reading workflow; for adjacent class cuts, see HIV antiretrovirals and bisphosphonates in FAERS.

Methodology, in one paragraph

A report is counted for the class when an MS DMT name appears anywhere in that report's drug list — as a suspect, concomitant, or interacting drug — using a substring match across the drug_substances, drug_generics, and drug_brands fields. Because a single report can name several drugs (sequential DMT switches are common), the per-molecule totals sum to more than the 820,731 class-level (union, deduplicated) reports. A "serious" report is any report the FDA coded as serious; a report counts toward death when the seriousness field carries a death flag or the outcome field carries a Fatal outcome. Reactions are MedDRA Preferred Terms, case-normalized. A few molecules in this class also carry non-MS indications — natalizumab in Crohn's disease, ofatumumab historically in CLL, cladribine in leukemia — so a minority of reports reflect those uses; the indication field confirms multiple sclerosis dominates at 607,361 reports. This "any role" convention is intentionally inclusive and matches the other class cuts in this series.

Reporting volume, by molecule

Read this table as a cumulative, all-time picture, not a current-market snapshot. The legacy injectable interferons and glatiramer, plus natalizumab's intensively monitored REMS reporting, dominate the historical totals; dimethyl fumarate and fingolimod carry large oral-era volumes. The anti-CD20 antibodies ocrelizumab and ofatumumab — 91,578 reports combined — are the current commercial leaders and drive most recent-year reporting, but they have not yet accumulated the historical base of the older agents. The union count of 820,731 counts each report once regardless of how many DMTs it names.

Seriousness, mortality, and demographics

The 44.8 percent serious share is materially lower than the serious-skewed oncology and cardiology classes, consistent with a chronic, non-fatal, heavily patient-reported disease; the 3.3 percent death-flag rate is among the lowest of any class this publication has analyzed. The 73.3 percent female skew matches the roughly 3:1 female predominance of relapsing-remitting MS, and the median age of 49 reflects a long-treated, working-age population.

The reaction list: disease symptoms, treatment failure, and infection

The list divides into three coherent clusters. Disease symptoms and disability — fatigue (68,440), gait disturbance (33,620), memory impairment (26,625), hypoaesthesia (24,186), falls (35,772) — are the reported burden of MS itself, and their prominence reflects the consumer-heavy reporting described below. Treatment failure — multiple sclerosis relapse (60,614) and drug ineffective (31,397) — is breakthrough disease, the primary driver of escalation from moderate-efficacy orals to high-efficacy antibodies. Class-specific drug reactions and infection — flushing (dimethyl fumarate), influenza-like illness (interferon), and the infection signal of urinary tract infection (19,320), COVID-19 (17,072), and herpes zoster (6,928) — track the immunosuppressive high-efficacy agents. Progressive multifocal leukoencephalopathy (PML), rare in count at 2,769 reports, is the signal that shapes the class's regulatory posture out of all proportion to its frequency.

The consumer-dominated reporter mix, and why lawyers are absent

This is the defining structural feature of the MS DMT class in FAERS, and it holds across the entire history: 64.2 percent of reports are consumer-filed, against just 137 lawyer reports in a database of 820,731. The contrast with other classes is stark — HIV antiretrovirals run roughly 13 percent lawyer-filed on the back of the tenofovir litigation, and even bisphosphonates sit near 2.4 percent. Two forces drive the consumer share: manufacturer patient-support hubs (Ocrevus, Kesimpta's Alongside, Tysabri's ActiveAccess) that employ nurses and case managers in frequent contact with patients, and the limited specialty-pharmacy networks (Accredo, CVS Specialty, AllianceRx) that conduct proactive clinical outreach at every refill. The near-absence of lawyers reflects the lack of mass-tort litigation: the class's signature risks — PML, infection — are labeled, monitored trade-offs accepted for high efficacy, not the basis of product-liability campaigns. The analytic consequence: this signal is rich in subjective, quality-of-life terms (fatigue, memory impairment) and requires clinical validation before it is read as objective toxicity.

PML and the natalizumab TOUCH REMS

No MS DMT read is complete without progressive multifocal leukoencephalopathy — a rare, often fatal demyelinating brain disease caused by reactivation of the JC virus, and the signature risk of natalizumab (Tysabri). PML forced natalizumab's temporary market withdrawal in 2005 and its return under the restrictive TOUCH Prescribing Program REMS. Risk is stratified on three factors, all of which sit in specialty-pharmacy dispensing gates:

• JC virus antibody index. JCV-negative patients carry very low PML risk; among JCV-positive patients, risk rises with the antibody index, with prior immunosuppressant use, and with treatment duration beyond ~24 months — reaching roughly 1 in 100 to 1 in 200 in the highest-risk stratum.
• MRI surveillance. Regular MRI (often every 3–6 months in higher-risk patients) is used to catch asymptomatic PML; PML lesions are typically asymmetric, subcortical, and non-enhancing, unlike the periventricular, often enhancing lesions of an MS relapse.
• Extended interval dosing. Dosing natalizumab every six weeks rather than four has been associated with substantially lower PML risk while preserving efficacy, and is increasingly written into medical-necessity criteria for JCV-positive patients.

The 2,769 PML reports in FAERS also include cases coded under fingolimod and the anti-CD20 antibodies, which is why JCV-index and MRI monitoring now extend beyond natalizumab. For specialty pharmacists, verifying TOUCH enrollment and JCV testing is a hard dispensing gate.

S1P receptor modulator first-dose and monitoring rules

The sphingosine-1-phosphate (S1P) receptor modulators — fingolimod (87,875 mentions), ozanimod, siponimod, ponesimod — carry a distinct monitoring profile because S1P receptors sit on cardiac and ocular tissue as well as lymphocytes:

• First-dose cardiac monitoring. Fingolimod requires a 6-hour first-dose observation with hourly heart rate and blood pressure and pre/post ECG, because initiation can cause transient bradycardia and AV block. The newer selective modulators (ozanimod, siponimod, ponesimod) use a titration schedule that avoids routine first-dose observation — but siponimod and the others still require first-dose cardiac monitoring in patients with pre-existing cardiac conditions (for example, certain arrhythmias, heart failure, or conduction disease), so the cardiac history gate does not disappear with the newer agents.
• Macular edema. S1P modulators raise the risk of macular edema; baseline and follow-up ophthalmologic exams (around 3–4 months) are recommended, with extra caution in diabetes or uveitis.
• Hepatic monitoring. Transaminase elevations are common; baseline and periodic liver function tests are required, with therapy held if transaminases exceed five times the upper limit of normal.

Abrupt discontinuation of an S1P modulator (notably fingolimod) can trigger severe rebound relapse, a specialty-pharmacy continuity concern when prior authorization lapses.

Fumarates: flushing, GI, and the lymphopenia–PML link

The fumarates — dimethyl fumarate (Tecfidera, 122,095 mentions), diroximel fumarate (Vumerity, 11,430), and monomethyl fumarate (Bafiertam, 899) — are the highest-volume oral sub-class in the cohort, and their reaction fingerprint is specific. Flushing (23,027 class reports) and influenza-like illness overlap with the dimethyl fumarate initiation reaction that drives early discontinuation, and the gastrointestinal terms (abdominal discomfort, diarrhoea, nausea) reflect the GI intolerance that diroximel fumarate was specifically formulated to reduce. The safety term that matters for monitoring, though, is lymphopenia (3,549 class reports): prolonged fumarate-induced lymphopenia — particularly a sustained absolute lymphocyte count below 0.5 × 10⁹/L — is the mechanism behind the rare PML cases reported with dimethyl fumarate, which is why the label mandates a baseline complete blood count and periodic absolute-lymphocyte-count monitoring, with treatment interruption for severe, prolonged lymphopenia. For access teams, the reproducible read is that generic dimethyl fumarate is a defensible first-step oral, but its coverage criteria should carry the ALC-monitoring requirement rather than treat it as a low-touch generic.

Alemtuzumab: high efficacy, secondary autoimmunity, and a REMS

Alemtuzumab (Lemtrada, 19,281 mentions) is the class's clearest example of an efficacy-versus-safety trade that lives entirely in the monitoring layer. As an anti-CD52 depleting antibody given in two short annual courses, it produces durable disease control but a distinctive delayed toxicity: secondary autoimmunity as the immune system reconstitutes. The label carries a boxed warning for autoimmune conditions (immune thrombocytopenia, anti-glomerular-basement-membrane nephropathy, and autoimmune thyroid disease), serious infusion reactions, and an increased risk of malignancy, and the drug is available only through a restricted REMS. The operational consequence — reflected in the infusion-related-reaction (4,283) and thyroid signals in the data — is 48 months of monthly monitoring after the last infusion: complete blood counts with differential, serum creatinine, urinalysis, and periodic thyroid function tests. For specialty pharmacy and neurology practices, the alemtuzumab access gate is not the infusion itself but the four-year monitoring commitment, and reauthorization and site-of-care policy should be written around it.

Relapse versus progression: reading the escalation signal

For clinical and market-access teams the most decision-relevant split in the reaction list is breakthrough disease versus neurodegeneration. Multiple sclerosis relapse (60,614) and drug ineffective (31,397) mark acute treatment failure — a new relapse or fresh MRI activity on therapy — and are the primary triggers for escalation from a moderate-efficacy oral to a high-efficacy antibody. Gait disturbance (33,620), hypoaesthesia (24,186), memory impairment (26,625), and balance disorder (20,071) mark disability accumulation, which in secondary- and primary-progressive MS proceeds partly independently of relapses; their prominence is the reproducible reminder that even high-efficacy B-cell depletion and S1P modulation do not fully arrest progression, keeping neurodegeneration an unmet need. The practical rule for reauthorization criteria: treat relapse and "drug ineffective" as escalation evidence, but anchor comparative-efficacy judgments to head-to-head trials and registries such as MSBase, not to spontaneous-report volumes that scale with how many patients are on each drug.

Specialty-pharmacy and benefit dynamics

MS DMT access is high-cost and administratively dense. WAC list prices run from roughly $65,000 to over $100,000 per year, so manufacturer copay programs and foundation assistance are central to access — see the Ocrevus subcutaneous vs IV access guide, the Kesimpta (ofatumumab) access guide, and the Tysabri/Tyruko natalizumab biosimilar access guide. Infused DMTs are billed under the medical benefit with HCPCS J-codes (J2350 for ocrelizumab, J2323 for natalizumab) via buy-and-bill or white-bagging, while self-injected ofatumumab and oral DMTs route through the pharmacy benefit and specialty fulfillment. Payers apply step therapy — commonly requiring a preferred generic oral (generic dimethyl fumarate or teriflunomide) or preferred injectable before a high-efficacy antibody — and reauthorization typically requires documented stability (no increased relapse frequency, stable MRI, adherence records).

The reporting trajectory, by year

The trajectory reflects a class with a large, mature reporting base rather than a safety trend. Volume jumped after 2009 as natalizumab's intensively monitored TOUCH REMS reporting and the first oral agents came online, peaked in 2013 (73,390) around the launch surge of dimethyl fumarate and the height of interferon and fingolimod reporting, and has trended down since 2022 as the legacy injectables fade from use and reporting consolidates toward the anti-CD20 antibodies and a smaller number of high-efficacy agents. The consumer-heavy hub-and-specialty-pharmacy reporting engine — not litigation or a new signal — sustains the high annual volume. (Years omitted from the table fall on the same trend line; 2026 is a partial year through the extract cut-off.)

What this means for pharmacovigilance, medical-affairs, and access teams

• Interpret this signal through its reporter mix. At 64.2 percent consumer-filed, the class is rich in quality-of-life terms (fatigue, memory impairment); validate clinically before treating them as toxicity.
• PML is the durable regulatory pressure point, not the raw count. At 2,769 reports it is rare, but JCV-index stratification, MRI surveillance, and extended-interval dosing remain the access and safety scaffolding for natalizumab and increasingly the high-efficacy agents.
• Keep the S1P cardiac gate for at-risk patients. The newer modulators avoid routine first-dose observation but still need cardiac monitoring in patients with cardiac history; do not write criteria that drop it entirely.
• Read relapse and "drug ineffective" as escalation drivers, not efficacy rankings. Multiple sclerosis relapse (60,614) and drug ineffective (31,397) are large partly because so many patients are treated; use head-to-head trials and registries for comparative efficacy.
• Protect S1P and natalizumab continuity. Rebound relapse on abrupt discontinuation makes prior-authorization lapses a clinical risk, not just an administrative one.
• Carry monitoring requirements into coverage criteria for the "generic" orals. Generic dimethyl fumarate and teriflunomide are high-value first steps, but the fumarate lymphopenia–PML link and teriflunomide hepatic and teratogenicity monitoring mean their criteria should preserve the lab-monitoring cadence, not treat them as low-touch generics.

FAQ

Does FAERS prove MS DMTs caused these events?

No. FAERS is spontaneous and denominator-free; reports reflect association, not causation, and are subject to reporting bias, missing data, and duplicates. The infection and PML signals are consistent with the known mechanisms of the high-efficacy agents, but the counts are not incidence.

Why is the lawyer-reporter share so low?

Just 137 of 820,731 reports are lawyer-filed (under 0.02 percent), because there has been no mass-tort litigation in MS. The class's signature risks — PML, infection — are labeled, monitored trade-offs accepted for high efficacy, so no legal recruitment campaigns drive retrospective reporting, unlike the tenofovir HIV litigation.

Do the anti-CD20 antibodies really lead the class?

They lead current reporting, not the cumulative all-time totals. Over full history, interferon beta (222,546), natalizumab (179,335), and dimethyl fumarate (122,095) top the per-molecule counts because of decades of exposure; ocrelizumab and ofatumumab (91,578 combined) are the current commercial leaders but have a shorter reporting history.

How should teams read the infection signal?

Urinary tract infection (19,320), COVID-19 (17,072), and herpes zoster (6,928) concentrate in the B-cell-depleting and other high-efficacy agents, consistent with impaired humoral immunity and hypogammaglobulinemia on prolonged anti-CD20 therapy — a reason vaccination status and immunoglobulin monitoring belong in long-term management.

Are natalizumab biosimilars changing the access picture?

Yes. A natalizumab biosimilar (Tyruko) is now available and adds a lower-cost option within the same intensively monitored pathway. Biosimilar substitution does not relax the PML safeguards — JC virus antibody-index testing, MRI surveillance, and the TOUCH-style REMS gates follow the molecule, not the brand — so the monitoring burden and specialty-pharmacy dispensing checks are unchanged. For access teams the biosimilar is a cost lever, not a monitoring-simplification lever; see the Tysabri/Tyruko natalizumab biosimilar access guide for the coverage detail.

Sources

• US FDA, openFDA FAERS (Adverse Event Reporting System) extract, export dated 2026-06-08 (20,328,575 total reports). Class-union, per-molecule, outcome, reaction, reporter, and indication aggregates computed by PharmaDossier from the public FAERS extract using an any-role substring match across drug substance, generic, and brand fields. https://open.fda.gov/data/faers/
• US FDA, Tysabri (natalizumab) prescribing information and TOUCH Prescribing Program REMS — PML risk stratification by JC virus antibody status, prior immunosuppressant use, and treatment duration. https://www.accessdata.fda.gov/scripts/cder/daf/
• US FDA, Gilenya (fingolimod), Mayzent (siponimod), Zeposia (ozanimod), and Ponvory (ponesimod) prescribing information — first-dose observation and cardiac-monitoring requirements. https://www.accessdata.fda.gov/scripts/cder/daf/
• National Multiple Sclerosis Society, Disease-Modifying Therapies for MS — class overview and mechanisms. https://www.nationalmssociety.org/managing-ms/treating-ms/disease-modifying-therapies
• Ryerson LZ, Foley J, Chang I, et al. "Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing" (TOUCH database analysis). Neurology 2019;93(15):e1452-e1462, doi:10.1212/WNL.0000000000008243. https://www.neurology.org/doi/10.1212/WNL.0000000000008243